152 results about "Hepatitis B virus" patented technology

The present invention relates generally to compositions, systems and methods for modulating hepatitis B virus (HBV) by targeting gene repression. In particular, the present invention provides an epigenetically modified DNA targeting system, such as a CRISPR-Cas / guide RNA (gRNA) system, for transcriptional repression of hepatitis B virus genes to promote cell phenotypes that lead to reduced HBV infection. In some embodiments, the epigenetically modified DNA targeting systems of the present invention bind to or target a target site of at least one gene in the hepatitis B virus DNA sequence or a regulatory element thereof in a cell. In some aspects, the systems provided herein relate to transcriptional repression of one or more hepatitis B virus genes and / or regulatory elements thereof. In some aspects, the invention also provides methods and uses associated with the provided compositions, such as in repression of hepatitis B virus replication and expression associated with hepatitis B infection.

The invention discloses a hepatitis B virus monoclonal neutralizing antibody SY-4 as well as preparation and application thereof. The hepatitis B virus monoclonal neutralizing antibody is SY-4 and consists of a heavy chain and a light chain paired with the heavy chain, the amino acid sequences of the CDR1, the CDR2 and the CDR3 of the heavy chain of the SY-4 are DFSFSSHA, ISSYDGGTT and AKEGNAFRYFGWLPDYQYFGMDV in sequence, and the amino acid sequences of the CDR1, the CDR2 and the CDR3 of the light chain of the SY-4 are QRINSRY, AAS and QQYGNSPLCS in sequence. The hepatitis B virus monoclonal neutralizing antibody SY-4 provided by the invention is an HBV neutralizing antibody, has ADCP activity, can crossly recognize various HBV genotypes HBsAg, has a good biological function, and provides a new candidate antibody for prevention and treatment of hepatitis B virus.

The present disclosure encompasses a lipid nanoparticle (LNP) comprising a polypeptide comprising a nucleic acid sequence encoding an engineered meganuclease that binds and cleaves a recognition sequence within a Hepatitis B virus (HBV) genome. Further, the disclosure encompasses pharmaceutical compositions comprising the LNPs, and the use of such compositions for inactivating a pol gene of an HBV genome or an HBV genome fragment in a cell and treating HBV infections or diseases associated with HBV infections.

This disclosure provides an immunoassay with exceptional sensitivity for detecting a target antigen in a sample. In one disclosure, the capture and detection steps of such an assay utilize recombinant antibodies. The disclosed immunoassay may find specific applications in the detection of HBV antigen.

Disclosed herein is a novel tool to associate protein cargo molecules to the inside and / or outside of a Hepatitis B Virus (HBV) virus-like particle (VLP). The novel tool being composed of a sulfamoylbenzamide (SBA) antiviral, linker, and protein.

The present disclosure provides methods for treating HBV infection using combination therapies, and related kits and compositions for use. The components of the combination therapies may include one or more of an anti-HBV antibody; an siRNA that targets an HBV mRNA; interferon-α; and a nucleos(t)ide reverse transcriptase inhibitor (NRTI).

An antisense oligonucleotide and the use thereof. A series of ASOs are designed on the basis of the genome sequence of a hepatitis B virus (HBV), and are modified by means of using a specific modification mode. Cell and animal experiment results show that some modified ASOs obtained by means of using the specific modification mode can significantly reduce the expression of one or more HBV genes and block the life cycle of viruses, and therefore can be used to develop drugs for treating HBV infection-related diseases.

An endocyclic thiamidoamide-arylamide compound and a pharmaceutical composition comprising said compound are described, as well as the use of the same or of the pharmaceutical composition in the treatment of hepatitis B. In particular, a compound that can be used as an inhibitor of HBV replication and that has the structure shown in chemical formula (L), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt, hydrate, or solvate thereof, is described.

The invention relates to a reagent, a kit and a method for quantitative detection of HBV (hepatitis B virus) nucleic acid, specifically, the preparation comprises (a) a first upstream primer with a nucleotide sequence as shown in SEQ ID NO: 1, a first downstream primer with a nucleotide sequence as shown in SEQ ID NO: 2 and a first probe with a nucleotide sequence as shown in SEQ ID NO: 3; and / or (b) a second upstream primer with a nucleotide sequence as shown in SEQ ID NO: 4, a second downstream primer with a nucleotide sequence as shown in SEQ ID NO: 5 and a second probe with a nucleotide sequence as shown in SEQ ID NO: 6. The detection reagent, kit or method disclosed by the invention is good in specificity, high in sensitivity and complete in gene coverage and has an excellent effect on a large-volume sample.

The present invention provides compositions and methods for novel digital PCR (dPCR) assay designs (droplet digital or other systems) for the detection and quantification of multiple Hepatitis B virus (HBV) gene targets. The compositions and methods can further include a non-extendible blocker oligonucleotide to reduce nonspecific inter-amplicon extension.

The present application relates to the field of biomedicine, and provides an epigenetic editing tool for targeting a hepatitis B virus gene and a use thereof.

The present disclosure relates to double stranded RNA agents targeting the hepatitis B virus (HBV) genome, and methods of using such agents to inhibit expression of one or more HBV genes and methods of treating subjects having an HBV infection or HBV-associated disorder, e.g., chronic hepatitis B infection.

The present disclosure includes synthetic methods for preparing certain substituted 1-aryl-1′-heteroaryl and 1,1′-biheteroaryl compounds, which can be used to treat, ameliorate, and / or prevent hepatitis B virus (HBV) infections in a patient.

The invention discloses a traditional Chinese medicine composition for treating fatty liver and reducing hepatitis B virus load. The traditional Chinese medicine composition is prepared from the following raw material medicines: prepared rehmannia root, rhizoma polygonati (processed), radix asparagi, schisandra chinensis, hawthorn leaf, glossy privet fruit, oriental wormwood, radix curcumae, illicium verum and salvia miltiorrhiza. According to the technology of the invention, liver treatment is a preparation based on compatibility of traditional Chinese medicine syndrome differentiation in which liver, spleen and kidney are treated at the same time, fat in the liver can be effectively removed, damage of hepatitis B virus to the liver can be reduced, hepatitis B virus reproduction can be effectively inhibited, the load of hepatitis B virus can be reduced, and multiple curative effects of liver treatment, liver nourishing and liver protection can be realized; the traditional Chinese medicine composition is superior to other treatment medicines and treatment technologies for fatty liver in modern medicine. The method can be widely applied to the fields of medicines, functional foods, health-preserving and health-care products, common foods and beverages and the like.

To provide a method for treating hepatitis B virus (HBV) infection in a subject.SOLUTION: Provided is a method comprising administering to the subject a single-dose pharmaceutical composition comprising an antibody having a specific sequence that binds to HBsAg.SELECTED DRAWING: Figure 3A

Provided in the present application are a glycosylated fusion protein, a nucleic acid molecule, an expression vector, a host cell and the use thereof. A first aspect of the present application provides the glycosylated fusion protein, comprising a murine Fc variant and a hepatitis B virus antigen, wherein the murine Fc variant is obtained by performing amino acid mutation and non-mammalian glycosylation modification on a murine Fc fragment, the murine Fc variant comprises at least one of alanine at position 223, alanine at position 228, alanine at position 230, leucine at position 330, and glutamic acid at position 332, the glycosylation modification does not comprise sialic acid modification, and the positions are numbered according to the EU numbering system. The fusion protein can bind to DC cells and activate DC cells, and thus promote the proliferation and activation of specific T cells.

The present invention provides novel immunogenic peptides derived from the X and polymerase proteins of hepatitis B virus (HBV). These peptides contain epitopes that are well conserved among multiple HBV variants and are derived from regions of the proteins essential for viral replication. Furthermore, these novel HBV antigens bind to multiple HLA types and induce IFN-glucan synthesis in PBMCs from HBV-resolved individuals. γ Epitopes that elicit a response were identified.

In the field of Hepatitis B virus (HBV) detection, disclosed are a method for detecting HBcAg by means of using a double antibody sandwich method, and an antibody and kit for detecting HBcAg; also included is a monoclonal antibody that can be used in the immunological detection of HBcAg in a tissue or cell sample.

An object of the present invention is to provide a pharmaceutical composition useful as a novel anti-hepatitis B virus agent and a screening method. According to the present invention, there is provided a pharmaceutical composition that inhibits the production of a hepatitis B virus protein, in which the pharmaceutical composition inhibits the expression or the function of a protein belonging to the YTHDC family.

The invention features lentiviral transfer vectors that include heterologous nucleic acids to be introduced into a cell. The lentiviral transfer vector may be characterized by the following features: (a) including a cytomegalovirus (CMV) promoter; (b) including a polynucleotide encoding a partial gag protein that includes a mutated INS1 inhibitory sequence that reduces restriction of nuclear export of RNA; (c) not including a polynucleotide encoding the INS2, INS3, and INS4 inhibitory sequences of gag; (d) not including an SV40 origin of replication and / or an f1 origin of replication; (e) including a cPPT sequence that contains splice site; (f) including an EF1alpha promoter with intact splice donor and acceptor sites; and (g) including hepatitis B PRE with mutation in start codon of X protein ORF.

The present invention relates to a dual-target double-stranded RNA for treating hepatitis B, and a pharmaceutical composition. The dual-target double-stranded RNA comprises a first double-stranded RNA and a second double-stranded RNA, wherein one of the first double-stranded RNA and the second double-stranded RNA targets the hepatitis B virus (HBV) life cycle, and the other targets a host immune target PD-L1. The double-stranded RNA can simultaneously target the dual targets of HBV and host immune PD-L1, which can inhibit HBV replication while activating human immunity, and is therefore expected to bring about a clinical functional cure.

Provided herein are non-naturally occurring variants of the hepatitis B virus (HBV) Core protein, the HBV polymerase N-terminal domain, and the HBV polymerase C-terminal domain, as well as immunogenic fragments thereof. Fusion proteins comprising the HBV variants fused to a herpes simplex virus (HSV) glycoprotein (gD) sequence, as well as methods of using the fusion proteins, are also provided.

The present application relates to a method for targeting and modulating a hepatitis B virus gene, which method comprises administering a pharmaceutical composition for inhibiting the expression of a hepatitis B virus (HBV) gene in cells. The pharmaceutical composition contains: 1) an epigenetic-modifying drug component which contains a fusion peptide or a complex peptide, or a nucleotide encoding the fusion peptide or complex peptide, wherein the fusion peptide or complex peptide contains at least one DNA-binding domain, at least one epigenetic-modifying domain, and at least one transcription-regulatory domain, and 2) a small nucleic acid drug component capable of targeting HBV and intervening with the expression thereof.

The present disclosure relates to a novel vaccine strategy against hepatitis B virus (HBV) infection, which is a major cause of chronic liver disease and hepatocellular carcinoma worldwide. The disclosure provides fusion proteins that target dendritic cells (DCs), the key antigen-presenting cells of the immune system, and deliver HBV-derived peptides to both the major histocompatibility complex (MHC) class I and II pathways, thereby inducing strong and specific humoral and cellular immune responses against the viral envelope and core antigens. The disclosure also provides methods of using the fusion proteins for the prevention or treatment of HBV infection and its complications. The inventors have demonstrated in a mouse model that the DC-targeting HBV vaccine candidates can elicit robust antibody and T cell responses, which are essential for the clearance of the virus and the protection from chronic infection.

The utility model relates to a convenient-to-titrate hepatitis B virus five-item detection kit, which solves the technical problem that the dropping position is easy to be inaccurate when the existing detection kit detects dropping buffer solution, and comprises a sample adding hole, slots arranged on the side wall of a detection card body are symmetrically arranged on two sides of the sample adding hole, and the slots are arranged on the side wall of the detection card body. The detection card body is provided with a plurality of slots, the slots are detachably matched with arched limiting plates in a sliding manner, the inner sides of the lower ends of the limiting plates are fixedly provided with inserting blocks matched with the slots, the limiting plates are provided with limiting holes corresponding to the sample adding holes, and integrated disposable buffer solution devices are inserted into the limiting holes. After the limiting plate is inserted into the detection card body, a limiting foundation for subsequently dropwise adding a buffer solution can be fixed, and after a buffer solution device is arranged, the accuracy of dropwise adding the buffer solution can be improved, the buffer solution can be accurately dropwise added, meanwhile, the waste of the buffer solution is avoided, the buffer solution is saved, and only a small amount of buffer solution needs to be prepared.

This invention belongs to the field of affinity membrane and bioseparation technology, and provides a cellulose-based affinity membrane for hepatitis B virus (HBV), its preparation method, and its application. The affinity membrane consists of a base membrane and an affinity ligand immobilized on the base membrane. The base membrane is a carboxylated cellulose filter membrane or a carboxylated modified cellulose filter membrane. The affinity ligand is a biomolecule that specifically recognizes HBV surface antigen. The carboxyl groups of the base membrane and the amino groups of the affinity ligand are linked by amide bonds. Unreacted carboxyl groups on the base membrane are blocked by a blocking reagent. The carboxyl content of the base membrane is 400-1000 μmol / g, the pore size is 400-1000 nm, and the porosity is 30%-60%. The application refers to the use of the above-mentioned affinity membrane in the specific clearance of HBV from HBV-positive plasma. This invention can achieve efficient and specific clearance of HBV from plasma, maximally preserving the activity and function of normal plasma components, and improving the feasibility of industrial application.

The present invention relates to enhanced antisense oligonucleotides that are complementary to the Far Upstream Element-Binding Protein 1 (FUBP1) and are capable of reducing a FUBP1 target nucleic acid, such as FUBP1 mRNA. The invention relates to enhanced antisense oligonucleotides targeting FUBP1 or conjugates thereof for use in treating and / or preventing a hepatitis B virus (HBV) infection, in particular a chronic HBV infection. The invention in particular relates to the use of the enhanced antisense oligonucleotides targeting FUBP1 or conjugates thereof for destabilizing cccDNA, such as HBV cccDNA. The invention further relates to enhanced antisense oligonucleotides targeting FUBP1 or conjugates thereof for use in treating cancer. A pharmaceutical composition and its use in the treatment and / or prevention of an HBV infection, or its use in the treatment of cancer is also disclosed.

The invention discloses application of licoflavone A in resisting viral hepatitis B, and belongs to the technical field of medicine application. The licoflavone A is used for treating viral hepatitis B. The licoflavone A used in the invention shows good safety and tolerance in HepG2.2. 15 and HepG2.A64 cells, can play a role in resisting HBV under the condition of no obvious cytotoxicity, and has significant advantages compared with interferon drugs in the prior art with long treatment course, large side effect and poor tolerance.

The present disclosure relates to methods to generate an immune response for the treatment or prevention of hepatitis B virus infection. This disclosure also relates to methods to generate MHC-E and / or MHC-II restricted CD8+ T cells for the treatment or prevention of hepatitis B virus infection.